Literature DB >> 25081223

Decreases in activated CD8+ T cells in patients with severe hepatitis B are related to outcomes.

Yinong Ye1, Jing Liu, Qing Lai, Qiyi Zhao, Liang Peng, Chan Xie, Genglin Zhang, Shaoquan Zhang, Yufeng Zhang, Jianyun Zhu, Yangsu Huang, Zhaoxia Hu, Dongying Xie, Bingliang Lin, Zhiliang Gao.   

Abstract

BACKGROUND: Many studies on T helper (Th)1, Th2, T regulatory and Th17 cells have been carried out in acute-on-chronic liver failure (ACLF). However, CD8(+) T cell, as a main participant in immune-mediated injuries and defense against microorganisms, has seldom been studied in ACLF. AIMS: The purpose of this study was to investigate the CD8(+) T cell function, and the outcomes of patients with severe hepatitis [SH; serum bilirubin (SB) ≥ 10 mg/dl and prothrombin activity (PTA) < 60 %].
METHODS: Thirty-six patients with chronic HBV-associated SH were included. Twenty normal chronic hepatitis B (CHB) patients (2 < SB < 10 (mg/dl) and PTA ≥ 60 %) and 28 healthy volunteers were enrolled as control groups.
RESULTS: Twenty-six patients with SH were diagnosed with ACLF (SB ≥ 10 mg/dl and PTA ≤ 40 %). The non-recovered ACLFs (NR-ACLF) had higher HBV DNA loads than recovered ACLFs (R-ACLF) (6.03 ± 1.79 vs. 4.36 ± 1.61 (log10, IU/L)). The NR-ACLFs had the highest neutrophil:lymphocyte ratios (5.10 ± 2.37) (all P < 0.001; a = 0.05). The CHBs had higher perforin(+) and TCM (CD45RA(-)CD62L(hi)CCR7(+)) proportions [31.28 ± 19.51, 5.32 ± 3.57 (%)] compared to R-ACLFs (11.75 ± 15.35, 0.78 ± 0.76 (%); P = 0.004, 0.001, respectively), or NR-ACLFs (11.61 ± 5.79, 1.14 ± 0.67 (%); P = 0.006, 0.003). The non-ACLF SHs had higher CD38(+) proportions than R-ACLFs or NR-ACLFs (25.46 ± 8.02 vs. 16.24 ± 7.77 or 16.81 ± 6.30 (%), P = 0.039, 0.023).
CONCLUSIONS: High neutrophil:lymphocyte ratios and a decrease in activated CD8(+) T cells may be related to poor outcomes in patients with SH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25081223     DOI: 10.1007/s10620-014-3297-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

Review 1.  Effector and memory CD8+ T cell differentiation: toward a molecular understanding of fate determination.

Authors:  Gabrielle T Belz; Axel Kallies
Journal:  Curr Opin Immunol       Date:  2010-04-29       Impact factor: 7.486

2.  Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Shin Yasui; Yutaka Yonemitsu; Kenichi Fukai; Makoto Arai; Fumio Imazeki; Akihiro Suzuki; Hiroshi Suzuki; Tomohito Sadahiro; Shigeto Oda; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

Review 3.  The importance of immune dysfunction in determining outcome in acute liver failure.

Authors:  Charalambos Gustav Antoniades; Philip A Berry; Julia A Wendon; Diego Vergani
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

4.  Rapid flow cytometric method for measuring lymphocyte subset activation.

Authors:  V C Maino; M A Suni; J J Ruitenberg
Journal:  Cytometry       Date:  1995-06-01

Review 5.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

6.  Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.

Authors:  Ji-Yuan Zhang; Zheng Zhang; Fang Lin; Zheng-Sheng Zou; Ruo-Nan Xu; Lei Jin; Jun-Liang Fu; Feng Shi; Ming Shi; Hui-Fen Wang; Fu-Sheng Wang
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

7.  CD8+ T cells promote inflammation and apoptosis in the liver after sepsis: role of Fas-FasL.

Authors:  Doreen E Wesche-Soldato; Chun-Shiang Chung; Stephen H Gregory; Thais P Salazar-Mather; Carol A Ayala; Alfred Ayala
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

8.  Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells.

Authors:  A Cesano; S Visonneau; S Deaglio; F Malavasi; D Santoli
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

9.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

10.  Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates.

Authors:  Surojit Sarkar; Vandana Kalia; W Nicholas Haining; Bogumila T Konieczny; Shruti Subramaniam; Rafi Ahmed
Journal:  J Exp Med       Date:  2008-03-03       Impact factor: 14.307

View more
  4 in total

1.  Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Guojun Shen; Shuilin Sun; Jie Huang; Haohui Deng; Ying Xu; Zhanhui Wang; Xiong Tang; Xiaodong Gong
Journal:  Hepatol Int       Date:  2019-12-23       Impact factor: 6.047

2.  Interleukin-35 Suppresses CD8+ T Cell Activity in Patients with Viral Hepatitis-Induced Acute-on-Chronic Liver Failure.

Authors:  Lanlan Yang; Qian Zhang; Jie Song; Wudong Wang; Zhenjing Jin
Journal:  Dig Dis Sci       Date:  2020-01-24       Impact factor: 3.199

Review 3.  Human immune repertoire in hepatitis B virus infection.

Authors:  Qiao Zhan; Jing-Hang Xu; Yan-Yan Yu; Emily Lo Kk; Hani El-Nezami; Zheng Zeng
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

4.  PD-1 Involvement in Peripheral Blood CD8+ T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure.

Authors:  Xiaoshuang Zhou; Yidong Li; Yaqiu Ji; Tian Liu; Ninghui Zhao; Jiefeng He; Jia Yao
Journal:  J Clin Transl Hepatol       Date:  2021-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.